Buck Wealth Strategies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Buck Wealth Strategies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114	Buy	+2	New	+$110	﹤0.01%	1133

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

EHI

Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Buck Wealth Strategies's BMRN Position: Q2 2026 in Review

Buck Wealth Strategies opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 2 shares worth $114. The stake represents ﹤0.01% of the portfolio and ranks #1133 among its holdings.

270 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Buck Wealth Strategies held 2 shares of BioMarin Pharmaceuticals worth $114 as of Q2 2026.
BioMarin Pharmaceuticals was a new Buck Wealth Strategies position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Buck Wealth Strategies's portfolio in Q2 2026, its #1133 holding.
270 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Buck Wealth Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.